US · Healthcare · Biotechnology
EPS came in at 0.53 against a street estimate of 0.53 — a beat of 0.0%.
Analysts rate Bio-Techne Corp a buy (10 buy, 5 hold, 0 sell out of 15) with an average price target of $69.73.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.87% |
| Vanguard Capital Management, LLC | 6.53% |
| Morgan Stanley - Brokerage Accounts | 5.48% |
| FMR Inc | 5.07% |
| Vanguard Portfolio Management, LLC | 4.16% |
| State Street Corp | 3.77% |
| Wellington Management Company LLP | 3.29% |
| Geode Capital Management, LLC | 3.28% |
| Document | Date |
|---|---|
| Material agreement · Q2 2026 | 2026-06-26 |
| Reg FD disclosure · Q2 2026 | 2026-06-25 |
| Quarterly report · Q1 2026 | 2026-05-06 |
| Results announced · Q2 2026 | 2026-05-06 |
| Board / officer change · Q1 2026 | 2026-02-11 |
| Quarterly report · Q4 2025 | 2026-02-04 |
| Quarterly report · Q3 2025 | 2025-11-05 |
| Proxy statement · Q4 2025 | 2025-09-19 |
Readable in the app.
| Announcement | Date |
|---|---|
| Agreement and Plan of Merger with Merck KGaA announced Bio-Techne Corporation has agreed to be acquired by Merck KGaA (a major German pharmaceutical company) in an all-cash merger. Under the agreement dated June 25, 2026, Bio-Techne shareholders | 2026-06-26 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Bio-Techne Corp — free to start.
Google PlayApp StoreData updated 2026-08-05.